Search

Your search keyword '"Long term safety"' showing total 35 results
Start Over Descriptor "Long term safety" Journal american journal of gastroenterology
35 results on '"Long term safety"'

1. S382 Long-Term Safety of Budesonide Oral Suspension for Eosinophilic Esophagitis: An Integrated Safety Analysis of Phase 1–3 Clinical Trial Data

Author

Siddharth Bhatia, Nirav K. Desai, Ikuo Hirano, Sandeep Gupta, Evan S. Dellon, Wenwen Zhang, Abigail M. Wojtowicz, Margaret H. Collins, David A. Katzka, and Mena Boules

Subjects
Budesonide, medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, medicine.disease, Clinical trial, Internal medicine, Medicine, Long term safety, business, Eosinophilic esophagitis, Suspension (vehicle), medicine.drug
Published
2021

2. S853 Long-term Safety of Ozanimod in Patients with Moderately to Severely Active Ulcerative Colitis (UC) and Relapsing Multiple Sclerosis (RMS) Studies

Author

David T. Rubin, Jeffrey A. Cohen, Lorna Charles, Olga Alekseeva, Diego Silva, Silvio Danese, Bruce A.C. Cree, Hongjuan Li, Ann Katrin Petersen, Sonia Afsari, James K Sheffield, Douglas C. Wolf, and Fred D. Lublin

Subjects
Ozanimod, medicine.medical_specialty, Hepatology, business.industry, Multiple sclerosis, Gastroenterology, medicine.disease, Ulcerative colitis, chemistry.chemical_compound, chemistry, Internal medicine, Medicine, In patient, Long term safety, business
Published
2021

3. P055 Vedolizumab Treatment Persistence up to 5 Years: Post hoc Analysis in Vedolizumab-Naïve Patients From the GEMINI Long-Term Safety Study

Author

Richard A. Lirio, Dirk Demuth, Edward V. Loftus, Laurent Peyrin-Biroulet, Sashi Adsul, Haridarshan Patel, Stella Mokiou, and Severine Vermeire

Subjects
Therapy naive, Pediatrics, medicine.medical_specialty, Hepatology, business.industry, Post-hoc analysis, Gastroenterology, Treatment persistence, Medicine, Long term safety, business, Vedolizumab, medicine.drug
Published
2019

5. S1006 Long-Term Safety of Sirolimus in Liver Transplant Recipients

Author

Kamal Khorfan, Mohammad S. Siddiqui, Katie Latack, Taha Ashraf, and Dilip Moonka

Subjects
medicine.medical_specialty, Hepatology, business.industry, Sirolimus, Gastroenterology, Medicine, Long term safety, business, Intensive care medicine, medicine.drug
Published
2020

6. 806 Long-Term Safety and Efficacy of Risankizumab Treatment in Patients With Crohn’s Disease: 3-Year Interim Results From the Ongoing Phase 2 Open-Label Extension Study

Author

Arthur Kaser, Brian G. Feagan, Dawn Gustafson, Julián Panés, Xiaomei Liao, Kori Wallace, Olivier Dewit, Weijiang (Rachel) Duan, Marc Ferrante, Geert R. D'Haens, Edouard Louis, Jasmina Kalabic, and Filip Baert

Subjects
Pediatrics, medicine.medical_specialty, Crohn's disease, Risankizumab, Hepatology, business.industry, Extension study, Gastroenterology, medicine.disease, Phase (combat), Interim, medicine, In patient, Long term safety, Open label, business
Published
2019

7. Long-Term Safety, Efficacy and Pharmacokinetics of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) Monoclonal Antibody SHP647 in Crohnʼs Disease: The OPERA II Study

Author

Anindita Banerjee, Dino Tarabar, Satyaprakash Nayak, Steven W. Martin, William J. Sandborn, Dong Il Park, Xavier Hébuterne, Jochen Klaus, Stefan Schreiber, Walter Reinisch, Maria Kłopocka, Kenneth J. Gorelick, Edouard Louis, Scott D. Lee, Fabio Cataldi, and Geert DʼHaens

Subjects
Hepatology, biology, Cell adhesion molecule, medicine.drug_class, business.industry, Gastroenterology, Disease, Monoclonal antibody, Pharmacokinetics, Immunology, Addressin, biology.protein, medicine, Long term safety, business
Published
2018

8. Long-term Safety and Efficacy of Fecal Microbiota Transplantation in the Treatment of Clostridium difficile Infection in Patients With and Without Inflammatory Bowel Disease: A Tertiary Care Centerʼs Experience

Author

Janese Laster, Pawan Rastogi, Mark Mattar, Obada Tabbaa, and Joseph Alukal

Subjects
medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, Fecal bacteriotherapy, Clostridium difficile, medicine.disease, Inflammatory bowel disease, Tertiary care, Internal medicine, medicine, In patient, Long term safety, business
Published
2017

10. PYRAMID Registry: Long-term Safety of Adalimumab by Age in Patients With Crohnʼs Disease

Author

Gabriela Alperovich, Mareike Bereswill, Joel Petersson, Remo Panaccione, Geert DʼHaens, Jean-Frederic Colombel, Anne M. Robinson, Edward V. Loftus, Walter Reinisch, Jasmina Kalabic, Sofie Berg, and Jack Satsangi

Subjects
Pediatrics, medicine.medical_specialty, Hepatology, business.industry, Pyramid, Gastroenterology, Adalimumab, medicine, In patient, Long term safety, Disease, business, medicine.drug
Published
2017

12. An Open Label Long-Term Safety Trial (T3MPO-3) of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation (IBS-C): Presidential Poster Award

Author

David P. Rosenbaum, William D. Chey, and Anthony Lembo

Subjects
medicine.medical_specialty, Constipation, Hepatology, business.industry, Gastroenterology, medicine.disease, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, chemistry, 030220 oncology & carcinogenesis, Internal medicine, Medicine, In patient, Long term safety, medicine.symptom, Open label, business, Tenapanor, 030217 neurology & neurosurgery, Irritable bowel syndrome
Published
2018

13. Long-Term Safety in the Open-Label Period of a Phase 2a Study of Brazikumab, an Antibody Against Interleukin-23

Author

Carl Gommoll, Bruce E. Sands, Robert A. Gasser, and Silvio Danese

Subjects
030222 orthopedics, medicine.medical_specialty, Hepatology, biology, business.industry, Period (gene), Gastroenterology, Phase (combat), 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, biology.protein, Interleukin 23, 030212 general & internal medicine, Long term safety, Antibody, Open label, business
Published
2018

14. Long-Term Safety of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) Antibody SHP647 in Ulcerative Colitis: An Open-Label Extension Study (TURANDOT II)

Author

Joo Sung Kim, Xavier Hébuterne, Paul Hellstern, Severine Vermeire, Miloš Greguš, Kenneth J. Gorelick, Bruce Salzberg, Fabio Cataldi, Caleb Bliss, Tomas Vanasek, Miles P. Sparrow, Martina Goetsch, William J. Sandborn, Dino Tarabar, Walter Reinisch, Maria Kłopocka, and Silvio Danese

Subjects
Hepatology, biology, Cell adhesion molecule, business.industry, Extension study, Gastroenterology, medicine.disease, Ulcerative colitis, Cancer research, biology.protein, medicine, Addressin, Long term safety, Antibody, Open label, business
Published
2018

15. PYRAMID Registry: Long-term Safety and Effectiveness of Adalimumab by Baseline Immunomodulator Use in Patients With Crohnʼs Disease

Author

Jack Satsangi, Geert DʼHaens, Anne M. Robinson, Jean-Frederic Colombel, Edward V. Loftus, Gabriela Alperovich, Remo Panaccione, Jasmina Kalabic, Sofie Berg, Mareike Bereswill, Joel Petersson, and Walter Reinisch

Subjects
0301 basic medicine, Pediatrics, medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, Disease, 03 medical and health sciences, 030104 developmental biology, Pyramid, Adalimumab, medicine, In patient, Long term safety, business, Baseline (configuration management), medicine.drug
Published
2017

17. Long-Term Safety of Adalimumab in Clinical Trials in Adult Patients With Crohnʼs Disease or Ulcerative Colitis

Author

William J. Sandborn, Winnie Lau, Holly Read, Jean-Frederic Colombel, Gert Van Assche, Paul Rutgeerts, Laurent Peyrin-Biroulet, Remo Panaccione, Brandee Pappalardo, Stephen B. Hanauer, Subrata Ghosh, Bidan Huang, Anne M. Robinson, and Walter Reinisch

Subjects
medicine.medical_specialty, Hepatology, Adult patients, business.industry, Gastroenterology, Disease, medicine.disease, Ulcerative colitis, Clinical trial, Internal medicine, Adalimumab, medicine, Long term safety, business, medicine.drug
Published
2015

18. Long-Term Safety and Efficacy of Certolizumab Pegol Therapy in Patients With Moderate to Severe Crohnʼs Disease: 5-Year Results

Author

Scott D. Lee, Gordana Kosutic, Cem Kayhan, Ziad Younes, Iram Hasan, Theadore Ptak, Ira Shafran, Marshall Spearman, Jason Coarse, Philip B. Miner, and William J. Sandborn

Subjects
Moderate to severe, Pediatrics, medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, medicine, In patient, Disease, Long term safety, Certolizumab pegol therapy, business
Published
2015

20. Long-term Safety of Vedolizumab for the Treatment of Ulcerative Colitis or Crohnʼs Disease

Author

William J. Sandborn, Brian G. Feagan, Irving H. Fox, Serap Sankoh, Jean-Frederic Colombel, Catherine Milch, Stephen B. Hanauer, Asit Parikh, Bruce E. Sands, Paul Rutgeerts, Remo Panaccione, Silvio Danese, and Geert R. D'Haens

Subjects
medicine.medical_specialty, Crohn's disease, Hepatology, business.industry, Gastroenterology, medicine.disease, Ulcerative colitis, Vedolizumab, Internal medicine, Medicine, Long term safety, business, medicine.drug
Published
2013

21. Long-term Safety and Tolerability of Naloxegol in Patients with Opioid-induced Constipation

Author

Mark Sostek, Peter Barker, William Y. Chey, Jaakko Lappalainen, Jan Tack, and Lynn R. Webster

Subjects
medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, Naloxegol, chemistry.chemical_compound, Opioid induced constipation, Tolerability, chemistry, Internal medicine, Medicine, In patient, Long term safety, business
Published
2013

22. Fecal Microbiota Transplantation: Long-Term Safety Issues

Author

Wael El-Matary

Subjects
Enterocolitis, medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, MEDLINE, Fecal bacteriotherapy, Clostridium difficile, Surgery, law.invention, Randomized controlled trial, law, Internal medicine, medicine, Vancomycin, Long term safety, medicine.symptom, business, medicine.drug
Abstract

To the Editor: Over the last decade, there has been piling evidence on the efficacy of fecal microbiota transplantation (FMT) as a treatment for recurrent Clostridium difficile infection (CDI). In their systematic review, which included 11 non-randomized controlled trial, Kassam et al. (1) are confirming the efficacy of FMT, as a treatment for recurrent CDI. Unfortunately this review did not include the only randomized controlled trial that was published recently comparing FMT, given via duodenal infusion, with vancomycin (2) as it was submitted in November 2012.

Published
2013

23. Long-Term Safety and Efficacy of Lubiprostone in Opioid-Induced Bowel Dysfunction in Patients with Chronic, Non-Cancer Pain: Results of a Phase 3, Open-Label Clinical Trial Presidential Poster

Author

Taryn Joswick, Elizabeth Lindner, Ryuji Ueno, Egilius Spierings, and Fasil Woldegeorgis

Subjects
medicine.medical_specialty, Hepatology, business.industry, Non cancer, Gastroenterology, Lubiprostone, Clinical trial, Bowel dysfunction, Opioid, Internal medicine, medicine, In patient, Long term safety, Open label, business, medicine.drug
Published
2012

24. Long-Term Safety of PA32540, a Coordinated Delivery Tablet of 325 mg of Enteric-Coated Aspirin and 40 mg of Immediate-Release Omeprazole in Secondary Cardiovascular Patients at Risk for Gastrointestinal Events

Author

Angel Lanas, John Fort, Jay L. Goldstein, Glenn M. Eisen, Byron Cryer, James M. Scheiman, and Ying Zhang

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Enteric coated aspirin, Gastroenterology, Medicine, Long term safety, Immediate release, business, Omeprazole, medicine.drug
Published
2013

26. Per Oral Endoscopic Myotomy (POEM) for Achalasia: Excellent Long-term Safety, Efficacy and Durability in a Large Single-center 4-year Series

Author

Kumkum Patel, Collin E. Brathwaite, Rani J. Modayil, Bhawna Halwan, Vischal Ghevariya, Dolorita Dejesus, James H. Grendell, Stavros N. Stavropoulos, and David Friedel

Subjects
medicine.medical_specialty, Hepatology, business.industry, Per-oral endoscopic myotomy, Gastroenterology, medicine, Achalasia, Long term safety, medicine.disease, Single Center, business, Surgery
Published
2013

27. Long-term Safety and Efficacy of Teduglutide for the Treatment of Intestinal Failure Associated with Short Bowel Syndrome: Final Results of the STEPS-2 Study, a 2-year, Multicenter, Open-label Clinical Trial

Author

Lauren K. Schwartz, Nader N. Youssef, Marek Pertkiewicz, Ken Fujioka, Palle Jeppesen, and Stephen OʼKeefe

Subjects
Pediatrics, medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, Short bowel syndrome, medicine.disease, Teduglutide, Clinical trial, chemistry.chemical_compound, chemistry, Intestinal failure, medicine, Long term safety, Open label, business
Published
2013

28. Long-term Safety of Adalimumab in Pediatric Patients with Crohnʼs Disease

Author

Roopal Thakkar, Jeffrey S. Hyams, Samantha Eichner, Frank M. Ruemmele, Robert N. Baldassano, Andreas Lazar, Joel R. Rosh, Jaroslaw Kierkus, William A. Faubion, and Yaqin Wang

Subjects
Pediatrics, medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, Adalimumab, medicine, Long term safety, Disease, business, medicine.drug
Published
2013

31. Navigating Long-Term Safety in Fecal Microbiota Transplantation

Author

Yuhong Yuan, Richard H. Hunt, Zain Kassam, and Christine H. Lee

Subjects
medicine.medical_specialty, Hepatology, medicine.diagnostic_test, Clostridioides difficile, business.industry, Gastroenterology, Colonoscopy, Fecal bacteriotherapy, Biological Therapy, Feces, Internal medicine, Immunology, medicine, Humans, Metagenome, Long term safety, business, Enterocolitis, Pseudomembranous
Abstract

3 . Sartour RB . Microbial infl uences in infl ammatory bowel diseases . Gastroenterology 2008 ; 134 : 577 – 94 . 4 . Finegold SM , Molitors D , Song Y . Gastrointestinal micro fl ora studies in late-onset autism . Clin Infect Dis. 2002 ; 35 : S6 – 16 . 5 . El-Matary W , Simpson R , Ricketts-Burns N . Fecal microbiota transplantation: are we opening a can of worms? Gastroenterology 2012 ; 143 : e19 . 6 . Yoon SS , Brandt LJ . Treatment of refractory/ recurrent C.diffi cile -associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients . J Clin Gastroenterol 2010 ; 44 : 562 – 6 .

Published
2013

33. Rifaximin has a Favorable Long-Term Safety Profile for Maintenance of Remission from Overt Hepatic Encephalopathy

Author

Samuel H. Sigal, Arun J. Sanyal, Kunal Merchant, Nathan M. Bass, Fred Poordad, Muhammad Y. Sheikh, Ravikumar Vemuru, Audrey L. Shaw, Enoch Bortey, Todd Frederick, Kevin D. Mullen, Shirley Huang, Bal Raj Bhandari, and William P. Forbes

Subjects
medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, medicine.disease, Rifaximin, chemistry.chemical_compound, chemistry, Internal medicine, medicine, Long term safety, business, Hepatic encephalopathy
Published
2009

35. DURABILITY AND LONG-TERM SAFETY OF ENTERYX® IMPLANTATION FOR GERD

Author

David A. Johnson, Glen A. Lehman, T. Raymond Foley, Robert A. Ganz, Lawrence B. Cohen, and James Aisenberg

Subjects
Pediatrics, medicine.medical_specialty, Hepatology, business.industry, Multicenter trial, Gastroenterology, GERD, Medicine, Long term safety, business, medicine.disease, Month follow up
Published
2004

Catalog

Books, media, physical & digital resources
See catalog results